Company profile
Strand Therapeutics
Where synthetic biology meets RNA therapeutics
- Industry
- Biotechnology Research
- Employees
- 124
- Headquarters
- Boston, Massachusetts
- Founded
- 2017
- LinkedIn followers
- 27,433
- Office locations
- 1
Strand Therapeutics company summary
Strand Therapeutics is a company in the Biotechnology Research industry, headquartered in Boston, Massachusetts, founded in 2017. On LinkedIn the company has around 124 employees and 27,433 followers. Its listed specialties include biotechnology, synthetic biology, RNA therapeutics, Immunotherapy.
What technology does Strand Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Strand Therapeutics
Strand Therapeutics is a clinical-stage biotechnology company pioneering programmable mRNA therapeutics to unlock the full potential of genetic medicines. Strand is applying its proprietary Signal Stack platform, which integrates EverScript circular RNA, AmpliScript self-replicating RNA, SignalPath targeted delivery, and logic-driven SignalLock genetic circuits to enable precise control of therapeutic activity across tissues and cell types and overcome foundational limitations in targeting, durability, and safety. Strand is advancing a pipeline with an initial focus on oncology and autoimmune disease. Its initial program, STX-001, an intratumorally delivered LNP-encapsulated self-replicating RNA expressing IL-12, has demonstrated preliminary evidence of systemic immune activation and anti-tumor activity in patients with advanced solid tumors who have progressed on prior therapies. Building on this early clinical validation, intravenously delivered STX-003 is designed for tumor-targeted expression and avoidance of off-target expression. STX-003, which is expected to enter the clinic in mid-2026, has the potential to be a major step forward for the fields of genetic medicine and oncology. Strand is also advancing STX-005, an in vivo CAR-T program designed to enable controlled, durable expression and repeat dosing. Founded by MIT synthetic biology pioneers, Strand has raised over $250 million and is headquartered in Boston, MA.
Specialties
Where is Strand Therapeutics located?
Strand Therapeutics lists 1 location.
Compare companies similar to Strand Therapeutics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Strand Therapeutics strandtx.com | Biotechnology Research | 124 | 2017 | Boston, Massachusetts |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Strand Therapeutics
What does Strand Therapeutics do?
Strand Therapeutics is a clinical-stage biotechnology company pioneering programmable mRNA therapeutics to unlock the full potential of genetic medicines. Strand is applying its proprietary Signal Stack platform, which integrates EverScript circular RNA, AmpliScript self-replicating RNA, SignalPath targeted delivery, and logic-driven SignalLock genetic circuits to enable precise control of therapeutic activity across tissues and cell types and overcome foundational limitations in targeting, durability, and safety. Strand is advancing a pipeline with an initial focus on oncology and autoimmune disease. Its initial program, STX-001, an intratumorally delivered LNP-encapsulated self-replicating RNA expressing IL-12, has demonstrated preliminary evidence of systemic immune activation and anti-tumor activity in patients with advanced solid tumors who have progressed on prior therapies. Building on this early clinical validation, intravenously delivered STX-003 is designed for tumor-targeted expression and avoidance of off-target expression. STX-003, which is expected to enter the clinic in mid-2026, has the potential to be a major step forward for the fields of genetic medicine and oncology. Strand is also advancing STX-005, an in vivo CAR-T program designed to enable controlled, durable expression and repeat dosing. Founded by MIT synthetic biology pioneers, Strand has raised over $250 million and is headquartered in Boston, MA.
How many employees does Strand Therapeutics have?
Strand Therapeutics has around 124 employees on LinkedIn.
Where is Strand Therapeutics headquartered?
Strand Therapeutics is headquartered in Boston, Massachusetts.
When was Strand Therapeutics founded?
Strand Therapeutics was founded in 2017.
Build a lead list from companies like Strand Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.